Associate Professor Anderson was trained in Microbiology and Molecular Virology at the University of Melbourne and Fairfield Hospital/Burnet Institute, under Professor Ian Gust and Stephen Locarnini. He received his PhD in 1989.
Since that time his work has focussed on understanding the structure and assembly of hepatitis viruses, and the use of this information to design better diagnostics, vaccines and antiviral therapies for control of major viral infections in humans.
Associate Professor Anderson has published more than 60 original research papers and invited chapters. He has presented on original research work at numerous national and international scientific meetings.
He has been active in translation of research into practical outcomes through commercial ventures and academic collaborations and is an inventor on 10 patent families.
Associate Professor Anderson has had a longstanding interest in the application of research to practical and commercial processes. This is reflected in contract and collaborative research agreements with the pharmaceutical and biotech industries since 1991.
In 2003 a portfolio of technologies from his laboratory relating to the control of infectious diseases (diagnostics, vaccines and antivirals) was licensed to the start-up biotech company Select Vaccines Limited (ASX:SLT). Three commercial diagnostic products are now sold worldwide based on this technology. A fourth (for diagnosis of active syphilis) is entering extensive laboratory trials in 2011; the vaccine technology has been sublicensed to ARTES Biotechnology in Germany.
Building on this expertise in rapid point of care diagnostics, Associate Professor Anderson and his laboratory team led by Mary Garcia is collaborating with: Professor Suzanne Crowe (Burnet Institute); Professor Alan Landay (Rush University, Chicago) and Professor Tom Denny (Duke University, Durham), to develop a point of care test for estimating CD4 T-cell numbers in patients. These tests are urgently needed to provide the tool to improve the management of HIV/AIDS in resource-poor settings.
Associate Professor Anderson and his team are also collaborating with Axxin Ltd in Richmond on the development of an inexpensive and robust instrument/reader for the CD4 test. This instrument provides greater accuracy and assists in training and quality control. The additional capabilities of the Axxin instrument will be important in the development of other much-needed point of care tests.
- NHMRC Senior Research Fellow (Level B)
- Associate Professor, Dept Microbiology and Immunology, University of Melbourne, Victoria, Australia
- Associate Senior Lecturer, Monash University, Victoria, Australia
- 2009: Visiting Associate Professor, Rush University Medical Centre, Chicago, Illinois, USA
- 2003-2008: Chief Scientific Officer, Select Vaccines Ltd
- 2001-2006: Senior Research Fellow (Level A), NHMRC
- 1996: Visiting Associate Research Professor, Department of Medicine, University of North Carolina, Chapel Hill, USA
- 1995-1999: Principal Investigator, Hepatitis E and B R&D syndicate, Macfarlane Burnet Centre for Medical Research, Victoria, Australia
- 1994-2004: Associate Senior Lecturer, Department of Microbiology, University of Melbourne, Victoria, Australia
- 1991-1993: Associate Lecturer, Department of Microbiology, University of Melbourne, Australia
- 1991-2002: Head, Hepatitis Research Unit, Macfarlane Burnet Centre for Medical Research, Australia
- 1990-1991: Senior Research Officer, Hepatitis Research Unit, Macfarlane Burnet Centre for Medical Research, Australia
- 1988-1989: Research Officer, Hepatitis Research Unit, Macfarlane Burnet Centre for Medical Research, Fairfield Hospital, Victoria, Australia
- B.Sc(Hons), University of Melbourne, Victoria, Australia
- PhD, University of Melbourne, Australia
- Accelerating ART initiation among Mothers and Infants (AAMI Study)
This project will trial the effectiveness, feasibility and acceptability of the novel POC VISITECT® CD4 test and POC LYNX HIV p24 early infant diagnostic (EID) test.
- Access Point Of Care
Increase access to lifesaving treatments for infectious diseases in hard-to-reach populations in resource-poor countries, by demonstrating the accuracy and feasibility of existing and novel point-of-care tests and enabling their implementation.
- APPRISE - Centre for Research Excellence
The Australian Partnership for Preparedness Research on Infectious Diseases Emergencies (APPRISE) will address the need for a rapid and effective emergency response to infectious diseases.
- Building a collaborative research agenda with members of ACABS
With funding from the Department of Industry Innovation, Science, Research and Tertiary Education, this grant is supporting collaboration between Australian and Chinese scientists in the field of biomedical research.
- Development of a point-of-care test for neonatal sepsis to improve diagnosis and treatment of newborn infections
Aimed at providing frontline healthcare workers with the ability to provide initial diagnosis in resource-constrained settings.
- Development of a simple, paper-based method of plasma separation and collection for HIV viral load testing
Aimed at improving access to HIV viral load assays in resource-limited settings.
- Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: A systematic review
A review to assess antiretroviral treatment monitoring in settings of decentralised HIV treatment and care in low and middle income countries.
- Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
This project involves the Richards Laboratory and Anderson Laboratory - Diagnostic Development.
- Improved diagnosis of active syphilis at point-of-care for the elimination of congenital syphilis
This project will optimise and validate an innovative and sensitive point-of-care (POC) test, which will rapidly and accurately diagnose active syphilis and allow for immediate treatment at the point of care.
- Improved diagnosis of active syphilis for the elimination of congenital syphilis
A project that will optimise and validate a point-of-care test that is able to both screen and confirm active syphilis cases.
- Methods for improved sensitivity of lateral flow tests
Integrating innovative techniques in nanotechnology to the development of robust and sensitive rapid assays.
- Molecular diagnostics for malaria elimination
This project involves the Richards Laboratory, Malaria and Tropical Diseases Group
- Novel non-nucleoside inhibitors of human hepatitis B virus (hHBV)
A new biological target for hHBV chemotherapy.
- Novel reagents for the serological diagnosis of tuberculosis
Using just a drop of blood, an innovative diagnostic test being developed at Burnet may be able to detect if a patient has tuberculosis (TB).
- Performance of an innovative, instrument-free, low-cost, rapid point-of-care CD4 test for accelerating initiation of antiretroviral interventions for HIV 1-infected pregnant women in resource-constrained settings
In high-burden countries, HIV is a significant cause of maternal death. A simple and accurate instrument-free, low-cost POC CD4 test could reduce loss to follow-up associated with centralised laboratory-based testing.
- Point-of-care alanine aminotransferase (ALT) diagnostic development
Nanjing BioPoint Diagnostic Technology Co. Ltd will undertake development of a new diagnostic for detecting liver disease.
- Strengthening the control of tuberculosis: China and Australia's partnership
With funding support from the Australia-China Council, Burnet is collaborating with the Institute for Pathogen Biology in Beijing on developing novel assays for improved tuberculosis serology.
- VISITECT® CD4
VISITECT® CD4 is an affordable HIV point-of-care test developed by Burnet but licensed to Omega Diagnostics.
- Xpert Ultra and GeneXpert Omni for the diagnosis of tuberculosis at the microscopy centre level: Papua New Guinea
The PNG Central Public Health Laboratory, with the PNG Institute for Medical Research and the Burnet Institute, is leading the PNG arm of a randomized control trial of a new Tuberculosis Point of Care technology.
- Performance of point-of-care CD4 testing technologies in resource-constrained settings: a systematic review and meta-analysis.
Pham MD, Agius PA, Romero L, McGlynn P, Anderson D, Crowe SM, Luchters S
BMC Infect Dis. 2016 Oct; 16(1):592
- Acceptability and feasibility of point-of-care CD4 testing on HIV continuum of care in low and middle income countries: a systematic review.
Pham MD, Agius PA, Romero L, McGlynn P, Anderson D, Crowe SM, Luchters S
BMC Health Serv Res. 2016 Aug; 16(1):343
- A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection of Trichomonas vaginalis.
Badman SG, Causer LM, Guy R, Tabrizi SN, Francis F, Donovan B, Whiley D; TTANGO investigators (Kaldor J, Wilson D, Regan D, Wand H, Shepard M, Ward J, Fairley K, Hengel B, Tangey A, Anderson D, Natoli L)
Sex Transm Infect. 2016 Aug; 92(5):350-352
- High resolution FTIR imaging provides automated discrimination and detection of single malaria parasite infected erythrocytes on glass.
Perez-Guaita D, Andrew D, Heraud P, Beeson J, Anderson D, Richards J, Wood BR
Faraday Discuss. 2016 Apr; 187:341-352
- Specific IgA Enhances the Transcytosis and Excretion of Hepatitis A Virus.
Counihan NA, Anderson DA
Sci Rep. 2016 Feb; 6:21855
- "I Do Feel Like a Scientist at Times": A Qualitative Study of the Acceptability of Molecular Point-Of-Care Testing for Chlamydia and Gonorrhoea to Primary Care Professionals in a Remote High STI Burden Setting.
Natoli L, Guy RJ, Shephard M, Causer L, Badman SG, Hengel B, Tangey A, Ward J, Coburn T, Anderson D, Kaldor J, Maher L; TTANGO Investigators (including Basil Donovan, David Wilson, David Regan, Handan Wand, David Whiley, Sepehr N. Tabrizi, Christopher Fairley)
PLoS One. 2015 Dec; 10(12):e0145993
- Public health implications of molecular point-of-care testing for chlamydia and gonorrhoea in remote primary care services in Australia: a qualitative study.
Natoli L, Guy RJ, Shephard M, Whiley D, Tabrizi SN, Ward J, Regan DG, Badman SG, Anderson DA, Kaldor J, Maher L; TTANGO investigator group
BMJ Open. 2015 Apr; 5(4):e006922
- An evaluation of a novel dual treponemal/non-treponemal point-of-care test for syphilis as a tool to distinguish active from past treated infection.
Causer LM, Kaldor JM, Conway DP, Leslie DE, Denham I, Karapanagiotidis T, Ryan C, Wand H, Anderson DA, Robertson PW, McNulty AM, Donovan B, Fairley CK, Guy RJ
Clin Infect Dis. 2015 Mar; 61(2):184-191
- Hepatitis E in Australian HIV-infected patients: an under-recognised pathogen?
Yong MK, Paige EK, Anderson D, Hoy JF
Sex Health. 2014 Sep; 11(4):375-378
- Site-Selective Solid-Phase Synthesis of a CCR5 Sulfopeptide Library to Interrogate HIV Binding and Entry.
Liu X, Malins LR, Roche M, Sterjovski J, Duncan R, Garcia ML, Barnes NC, Anderson DA, Stone MJ, Gorry PR, Payne RJ
ACS Chem Biol. 2014 Jun; 9(9):2074-2081
- Point-of-Care Testing for Chlamydia and Gonorrhoea: Implications for Clinical Practice.
Natoli L, Maher L, Shephard M, Hengel B, Tangey A, Badman SG, Ward J, Guy RJ on behalf of the TTANGO Investigators (including Guy R, Kaldor J, Donovan B, Wilson D, Wand H, Regan D, Causer L, Hengel B, Anderson D, Whiley D, Tabrizi SN, Fairley C)
PLoS One. 2014 Jun; 9(6):e100518
- Cold adaptation improves the growth of seasonal influenza B vaccine viruses.
Kim H, Schoofs P, Anderson DA, Tannock GA, Rockman SP
Vaccine. 2014 Mar; 32(21):2474-2479
- A Laboratory-Based Evaluation of Four Rapid Point-of-Care Tests for Syphilis.
Causer LM, Kaldor JM, Fairley CK, Donovan B, Karapanagiotidis T, Leslie DE, Robertson PW, McNulty AM, Anderson D, Wand H, Conway DP, Denham I, Ryan C, Guy RJ
PLoS One. 2014 Mar; 9(3):e91504
- A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the "TTANGO" trial protocol.
Guy RJ, Natoli L, Ward J, Causer L, Hengel B, Whiley D, Tabrizi SN, Donovan B, Fairley CK, Badman SB, Tangey A, Wand H, Shephard M, Regan DG, Wilson D, Anderson D, Kaldor JM
BMC Infect Dis. 2013 Oct; 13(1):485
- Point-of-care testing and the control of infectious diseases.
Mohd Hanafiah K, Garcia M, Anderson D
Biomark Med. 2013 Jun; 7(3):333-347
- Vectorial entry and release of hepatitis A virus in polarized human hepatocytes.
Snooks MJ, Bhat P, Mackenzie J, Counihan NA, Vaughan N, Anderson DA
J Virol. 2008 Sep; 82(17):8733-8742
- Double-antigen enzyme-linked immunosorbent assay for detection of hepatitis E virus-specific antibodies in human or swine sera.
Hu WP, Lu Y, Precioso NA, Chen HY, Howard T, Anderson D, Guan M
Clin Vaccine Immunol. 2008 Aug; 15(8):1151-1157
- Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza.
Goy K, Von Bibra S, Lewis J, Laurie K, Barr I, Anderson D, Hellard M, Ffrench R
Influenza Other Respi Viruses. 2008 Jul; 2(4):115-125
- Dual infection with hepatitis A and E viruses in outbreaks and in sporadic clinical cases: Cuba 1998-2003.
Rodríguez Lay Lde L, Quintana A, Villalba MC, Lemos G, Corredor MB, Moreno AG, Prieto PA, Guzmán MG, Anderson D
J Med Virol. 2008 May; 80(5):798-802
- Amiloride derivatives inhibit coxsackievirus B3 RNA replication.
Harrison DN, Gazina EV, Purcell DF, Anderson DA, Petrou S
J Virol. 2008 Feb; 82(3):1465-1473
- Virus-like particles: passport to immune recognition.
Grgacic EV, Anderson DA
Methods. 2006 Sep; 40(1):60-65
- Infrared fluorescent immunofocus assay (IR-FIFA) for the quantitation of non-cytopathic and minimally cytopathic viruses.
Counihan NA, Daniel LM, Chojnacki J, Anderson DA
J Virol Methods. 2006 Apr; 133(1):62-69
- The effect of antigen targeting sequences on antibody responses to hepatitis E virus DNA vaccines in rats and sheep.
Li F, Loke P, Healy A, Lightowlers MW, Gauci CG, Purcell DF, Anderson DA
Vaccine. 2006 Feb; 24(9):1367-1377
- Hepatitis E virus infection as a marker for contaminated community drinking water sources in Tibetan villages.
Toole MJ, Claridge F, Anderson DA, Zhuang H, Morgan C, Otto B, Stewart T
Am J Trop Med Hyg. 2006 Feb; 74(2):250-254
- A hydrophobic domain in the large envelope protein is essential for fusion of duck hepatitis B virus at the late endosome.
Chojnacki J, Anderson DA, Grgacic EVL
J Virol. 2005 Dec; 79(23):14945-14955
- Evaluation of a new rapid immunochromatographic assay for serodiagnosis of acute hepatitis E infection.
Myint KSA, Guan M, Chen HY, Lu Y, Anderson D, Howard T, Noedl H, Mammen MP
Am J Trop Med Hyg. 2005 Nov; 73(5):942-946
- Ion transport blockers inhibit human rhinovirus 2 release.
Gazina EV, Harrison DN, Jefferies M, Tan H, Williams D, Anderson DA, Petrou S
Antiviral Res. 2005 Aug; 67(2):98-106
- Structure and molecular virology.
Anderson DA, Cheng RH
Viral Hepatitis, 3rd Edition (Editors: Thomas H, Lemon S, Zuckerman A). 2005 Jul
- Comparison of a new immunochromatographic test to enzyme-linked immunosorbent assay for rapid detection of immunoglobulin m antibodies to hepatitis e virus in human sera.
Chen HY, Lu Y, Howard T, Anderson D, Fong PY, Hu WP, Chia CP, Guan M
Clin Diagn Lab Immunol. 2005 May; 12(5):593-598
- St, a truncated envelope protein derived from the S protein of duck hepatitis B virus, acts as a chaperone for the folding of the large envelope protein.
Grgacic EVL, Anderson DA
J Virol. 2005 May; 79(9):5346-5352
- Prevalence of antibodies to hepatitis E virus in residents of a district in Havana, Cuba.
Quintana A, Sanchez L, Larralde O, Anderson D
J Med Virol. 2005 May; 76(1):69-70
- Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A, Macgregor A, Borovec S, Hattarki M, Stuckly K, Anderson D, Goss NH, Oates A, Uren E
Biologicals. 2000 Sep; 28(3):129-136
- Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies.
Riddell MA, Li F, Anderson DA
J Virol. 2000 Sep; 74(17):8011-8017
- Infection of polarized cultures of human intestinal epithelial cells with hepatitis A virus: vectorial release of progeny virions through apical cellular membranes.
Blank CA, Anderson DA, Beard M, Lemon SM
J Virol. 2000 Jul; 74(14):6476-6484
- Core protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B viruses.
Gazina EV, Fielding JE, Lin B, Anderson DA
J Virol. 2000 May; 74(10):4721-4728
- Uncoating kinetics of hepatitis A virus virions and provirions.
Bishop NE, Anderson DA
J Virol. 2000 Apr; 74(7):3423-3426
- Recombinant subunit ORF2.1 antigen and induction of antibody against immunodominant epitopes in the hepatitis E virus capsid protein.
Li F, Riddell MA, Seow HF, Takeda N, Miyamura T, Anderson DA
J Med Virol. 2000 Apr; 60(4):379-386
- The explosive human immunodeficiency virus type 1 epidemic among injecting drug users of Kathmandu, Nepal, is caused by a subtype C virus of restricted genetic diversity.
Oelrichs RB, Shrestha IL, Anderson DA, Deacon NJ
J Virol. 2000 Feb; 74(3):1149-1157
- A vestigial X open reading frame in duck hepatitis B virus.
Lin B, Anderson DA
Intervirology. 2000 Jan; 43(3):185-190
- Seroprevalence of antibodies to hepatitis E virus in the normal blood donor population and two aboriginal communities in Malaysia.
Seow HF, Mahomed NM, Mak JW, Riddell MA, Li F, Anderson DA
J Med Virol. 1999 Oct; 59(2):164-168
- Serological evidence for swine hepatitis E virus infection in Australian pig herds.
Chandler JD, Riddell MA, Li F, Love RJ, Anderson DA
Vet Microbiol. 1999 Aug; 68(1-2):95-105
- ELISA for IgG-class antibody to hepatitis E virus based on a highly conserved, conformational epitope expressed in Escherichia coli.
Anderson DA, Li F, Riddell M, Howard T, Seow HF, Torresi J, Perry G, Sumarsidi D, Shrestha SM, Shrestha IL
J Virol Methods. 1999 Aug; 81(1-2):131-142
- Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells.
Torresi J, Li F, Locarnini SA, Anderson DA
J Gen Virol. 1999 May; 80 ( Pt 5):1185-1188
- Normal phosphorylation of duck hepatitis B virus L protein is dispensable for infectivity.
Grgacic EV, Lin B, Gazina EV, Snooks MJ, Anderson DA
J Gen Virol. 1998 Nov; 79 ( Pt 11):2743-2751
- Chromatographic removal and heat inactivation of hepatitis B virus during the manufacture of human albumin.
Adcock WL, MacGregor A, Davies JR, Hattarki M, Anderson DA, Goss NH
Biotechnol Appl Biochem. 1998 Oct; 28 ( Pt 2):169-178
- Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin.
Adcock WL, MacGregor A, Davies JR, Hattarki M, Anderson DA, Goss NH
Biotechnol Appl Biochem. 1998 Aug; 28 ( Pt 1):85-94
- Intracellular retention of duck hepatitis B virus large surface protein is independent of preS topology.
Gazina EV, Lin B, Gallina A, Milanesi G, Anderson DA
Virology. 1998 Mar; 242(2):266-278
- High level expression of the capsid protein of hepatitis E virus in diverse eukaryotic cells using the Semliki Forest virus replicon.
Torresi J, Meanger J, Lambert P, Li F, Locarnini SA, Anderson DA
J Virol Methods. 1997 Dec; 69(1-2):81-91
- Quantification of infectious duck hepatitis B virus by radioimmunofocus assay.
Anderson DA, Grgacic EV, Luscombe CA, Gu X, Dixon R
J Med Virol. 1997 Aug; 52(4):354-361
- Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked.
Li F, Torresi J, Locarnini SA, Zhuang H, Zhu W, Guo X, Anderson DA
J Med Virol. 1997 Jul; 52(3):289-300
- Hepatitis A virus subviral particles: purification, accumulation, and relative infectivity of virions, provirions and procapsids.
Bishop NE, Anderson DA
Arch Virol. 1997 Jan; 142(11):2147-2160
- Early interactions of hepatitis A virus with cultured cells: viral elution and the effect of pH and calcium ions.
Bishop NE, Anderson DA
Arch Virol. 1997 Jan; 142(11):2161-2178
- Locally acquired hepatitis E in the Northern Territory of Australia.
Heath TC, Burrow JN, Currie BJ, Bowden FJ, Fisher DA, Demediuk BH, Locarnini SA, Anderson DA.
Med J Aust. 1995 Mar; 162(6):318-319
- Restrictive events in the replication of hepatitis A virus in vitro.
D A Anderson, S A Locarnini, A G Coulepis, I D Gust
Intervirology. 1995 Jan; 24(1):26-32